Asthma and allergic inflammation modulators
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are tetrahydroquinoline derivatives.
1 . A compound having the formula (I):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
W is selected from the group consisting of aryl, heteroaryl, (C 1 -C 8 )alkyl and cyclo(C 3 -C 8 )alkyl;
L 1 is selected from the group consisting of C(O), SO 2 and (C 1 -C 4 )alkylene;
L 2 is selected from the group consisting of a single bond, C(O) and SO 2 ;
R 1 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl, aryl(C 1 -C 4 )alkoxy, aryl(C 1 -C 4 )alkenyl and heteroaryl;
R 2 and R 3 are independently hydrogen or (C 1 -C 8 )alkyl;
R 4 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl(C 1 -C 4 )alkyl, cyclo(C 3 -C 8 )alkyl(C 1 -C 4 )alkyl, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, carboxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl, carbamoyl(C 1 -C 4 )alkyl and carboxy(C 2 -C 4 )alkenyl;
each R 5 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 4 )alkoxy, thio(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, cyano, nitro, —CO 2 R′, —CONR′R″, —C(O)R′, —OC(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″CO 2 R′, —N(R′)C(O)NR″R′″, —NR′C( 2 )═NR″, —S(O)R′, —SO 2 R′, —SO 2 NR′R″, —N 3 and —CH(Ph) 2 ;
optionally, two adjacent R 5 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S;
R′, R″ and R′″ are independently selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl and heteroaryl;
optionally, when R′ and R″ or R″ and R′″ are attached to the same nitrogen atom, R′ and R″ or R″ and R′″ may be combined to form a 5-, 6-, 7- or 8-membered ring containing the nitrogen atom to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and
the subscript m is 0, 1, 2, 3 or 4;
with the proviso that said compound is other than
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-2-methyl-N-phenylpropanamide,
N-[1-(3-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylhexanamide,
N-[1-(4-ethylbenzoyl)-1,2,3,4-tetrahydro-2,8-dimethyl-4-quinolinyl]-N-(2-methylphenyl)-2-(2-naphthalenyloxy)acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(3-nitrobenzoyl)-4-quinolinyl]-hexanamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-chlorophenyl)-1,3-dioxo-1H-benz[de]isoquinoline-2(3H)-acetamide,
N-[1,1′-biphenyl]-3-yl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]acetamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-nitrophenyl)heptanamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-methoxyphenyl)-1,3-dioxo-1H-benz[de]isoquinoline-2(3H)-acetamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-methoxyphenyl)-2-methylpropanamide,
N-[1-(4-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylbutanamide, 2-phenoxy-N-phenyl-N-[1,2,3,4-tetrahydro-1-(2-methoxybenzoyl)-2-methyl-4-quinolinyl]acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]pentanamide,
N-(2-methylphenyl)-2-(2-naphthalenyloxy)-N-[1,2,3,4-tetrahydro-2,8-dimethyl-1-(4-propylbenzoyl)-4-quinolinyl]acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(4-nitrobenzoyl)-4-quinolinyl]octanamide,
N-[1-(4-ethylbenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-2-(2-naphthalenyloxy)-N-phenylacetamide,
N-[1-(4-ethylbenzoyl)-1,2,3,4-tetrahydro-2,8-dimethyl-4-quinolinyl]-N-(2-methylphenyl)-3-(4-nitrophenyl)-2-propenamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-2,2-dimethyl-N-phenylpropanamide,
N-(1-benzoyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenylpentanamide,
2-methyl-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl)propanamide,
2,2,2-trifluoro-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]acetamide,
N-[1-(4-ethylbenzoyl)-1,2,3,4-tetrahydro-2,8-dimethyl-4-quinolinyl]-N-(2-methylphenyl)-3-phenyl-2-propenamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(3methoxyphenyl)acetamide,
N-[1-(4-chlorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-1,3-dioxo-N-phenyl-1H-benz[de]isoquinoline-2(3H)-acetamide,
3-(4-nitrophenyl)-N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(4-propylbenzoyl)-4-quinolinyl]-2-propenamide,
N,3-diphenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]-2-propenamide,
N-[1-(2-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylhexanamide,
N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]hexanamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-methylphenyl)acetamide,
3-(4-nitrophenyl)-N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]-2-propenamide,
3-(4-methoxyphenyl)-N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]-2-propenamide,
N-[1-(4-chloro-3-nitrobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylacetamide,
1,3-dioxo-N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]-1H-benz[de]isoquinoline-2(3H)-acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(3-nitrobenzoyl)-4-quinolinyl]acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxypbenzoyl)-2-methyl-4-quinolinyl]hexanamide,
N-[1-(3-chlorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylacetamide,
N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-2-methyl-N-Response phenylpropanamide,
N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-2,2-dimethyl-N-phenylpropanamide,
N-[1-(3-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylacetamide,
N-[1-[4-(1,1-dimethylethyl)benzoyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylacetamide,
rel-N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylbutanamide,
rel-N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylacetamide,
rel-N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylheptanamide,
rel-N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylpentanamide,
N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]acetamide,
N-[1-(3,5-dinitrobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenylacetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(4-nitrobenzoyl)-4-quinolinyl]acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-1-(2-iodobenzoyl)-2-methyl-4-quinolinyl]acetamide,
N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]acetamide,
1,3-dihydro-1,3-dioxo-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-2H-isoinodole-2-acetamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenylhexanamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenylpentanamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenylbutanamide,
N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenylpropanamide,
1-benzoyl-1,2,3,4-tetrahydro-4-(N-phenylacetamido)quinaldine,
N-(1-benzoyl-6-chloro-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)acetanilide and
1-benzoyl-6-bromo-1,2,3,4-tetrahydro-4-(N-phenylacetamido)quinaldine.
2 . The compound of claim 1 , wherein L 2 is other then C(O) when R 4 is unsubstituted alkyl.
3 . The compound of claim 2 , wherein R 4 is selected from the group consisting of substituted (C 1 -C 8 )alkyl, aryl(C 1 -C 4 )alkyl, cyclo(C 3 -C 8 )alkyl(C 1 -C 4 )alkyl, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, carboxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl, carbamoyl(C 1 -C 4 )alkyl and carboxy(C 2 -C 4 )alkenyl.
4 . The compound of claim 3 , wherein R 4 is selected from the group consisting of aryl(C 1 -C 4 )alkyl, cyclo(C 3 -C 8 )alkyl(C 1 -C 4 )alkyl, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, carboxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl, carbamoyl(C 1 -C 4 )alkyl and carboxy(C 2 -C 4 )alkenyl.
5 . The compound of claim 1 , wherein W is selected from the group consisting of phenyl, naphthyl, biphenyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, pyrimidinyl, pyridazinyl, benzothiazolyl, purinyl, benzimidazolyl, indolyl, indazolyl, carbazolyl, carbolinyl, isoquinolyl, quinoxalinyl and quinolyl.
6 . The compound of claim 1 , wherein L 2 is C(O).
7 . The compound of claim 6 , wherein W is phenyl.
8 . The compound of claim 7 , having the formula (II):
wherein
each R 6 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 4 )alkoxy, thio(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, cyano, nitro, —CO 2 R′, —CONR′R″, —C(O)R′, —OC(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″CO 2 R′, —S(O)R′, —SO 2 R′ and —SO 2 NR′R″;
optionally, two adjacent R 6 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and the subscript n is 0, 1, 2, 3, 4 or 5.
9 . The compound of claim 1 , wherein R 1 is selected from the group consisting of (C 1 -C 8 )alkyl, phenyl, naphthyl, aryl(C 1 -C 4 )alkyl, aryl(C 1 -C 4 )alkoxy, aryl(C 1 -C 4 )alkenyl or heteroaryl.
10 . The compound of claim 9 , wherein R 1 is unsubstituted phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )alkoxy, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, nitro, cyano, aryl and aryloxy.
11 . The compound of claim 1 , wherein L 1 is C(O).
12 . The compound of claim 10 , wherein R 1 is unsubstituted phenyl or phenyl substituted with 1, 2 or 3 substituents selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )alkoxy, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, nitro, cyano, aryl and aryloxy.
13 . The compound of claim 11 , having the formula (III):
wherein
each R 7 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 8 )alkoxy, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkyl amino, di(C 1 -C 4 )alkylamino, nitro, cyano, aryl and aryloxy;
optionally, two adjacent R 7 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and
the subscript p is 0, 1, 2, 3, 4 or S.
14 . The compound of claim 13 , wherein the subscript p is 1.
15 . The compound of claim 14 , having the formula (IV):
16 . The compound of claim 1 , wherein R 3 is hydrogen.
17 . The compound of claim 1 , having the formula (V):
wherein
each R 6 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 4 )alkoxy, thio(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, cyano, nitro, —CO 2 R′, —CONR′R″, —C(O)R′, —OC(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″CO 2 R′, —S(O)R′, —SO 2 R′ and —SO 2 NR′R″;
optionally, two adjacent R 6 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S;
each R 7 is independently selected from the group consisting of halogen, (C 1 -Response C 8 )alkyl, (C 1 -C 8 )alkoxy, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, nitro, cyano, aryl and aryloxy;
optionally, two adjacent R 7 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and
the subscripts n and p are independently 0, 1, 2, 3, 4 or 5.
18 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of formula (I):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
W is selected from the group consisting of aryl, heteroaryl, (C 1 -C 8 )alkyl and cyclo(C 3 -C 8 )alkyl;
L 1 is selected from the group consisting of C(O), SO 2 and (C 1 -C 4 )alkylene;
L 2 is selected from the group consisting of a single bond, C(O) and SO 2 ;
R 1 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl, aryl(C 1 -C 4 )alkoxy, aryl(C 1 -C 4 )alkenyl and heteroaryl;
R 2 and R 3 are independently hydrogen or (C 1 -C 8 )alkyl;
R 4 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl(C 1 -C 4 )alkyl, cyclo(C 3 -C 8 )alkyl(C 1 -C 4 )alkyl, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, carboxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl, carbamoyl(C 1 -C 4 )alkyl and carboxy(C 2 -C 4 )alkenyl;
each R 5 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 4 )alkoxy, thio(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, cyano, nitro, —CO 2 R′, —CONR′R″, —C(O)R′, —OC(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″CO 2 R′, —N(R′)C(O)NR″R′″, —NR′C(NH 2 )═NR″, —S(O)R′, —SO 2 R′, —SO 2 NR′R″, —N 3 and —CH(Ph) 2 ;
optionally, two adjacent R 5 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S;
R′, R″ and R′″ are independently selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl and heteroaryl;
optionally, when R′ and R″ or R″ and R′″ are attached to the same nitrogen atom, R′ and R″ or R″ and R′″ may be combined to form a 5-, 6-, 7- or 8-membered ring containing the nitrogen atom to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and
the subscript m is 0, 1, 2, 3 or 4.
19 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of any one of claims 1 - 17 .
20 . A method for treating a disease or condition selected from the group consisting of asthma, allergic rhinitis, eczema, psoriasis, atopic dermatitis, fever, sepsis, systemic lupus erythematosus, diabetes, rheumatoid arthritis, multiple sclerosis, atherosclerosis, transplant rejection, inflammatory bowel disease and cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
W is selected from the group consisting of aryl, heteroaryl, (C 1 -C 8 )alkyl and cyclo(C 3 -C 8 )alkyl;
L 1 is selected from the group consisting of C(O), SO 2 and (C 1 -C 4 )alkylene;
L 2 is selected from the group consisting of a single bond, C(O) and SO 2 ;
R 1 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl, aryl(C 1 -C 4 )alkoxy, aryl(C 1 -C 4 )alkenyl and heteroaryl;
R 2 and R 3 are independently hydrogen or (C 1 -C 8 )alkyl;
R 4 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl(C 1 -C 4 )alkyl, cyclo(C 3 -C 8 )alkyl(C 1 -C 4 )alkyl, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, carboxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl, carbamoyl(C 1 -C 4 )alkyl and carboxy(C 2 -C 4 )alkenyl;
each R 5 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 4 )alkoxy, thio(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, cyano, nitro, —CO 2 R′, —CONR′R″, —C(O)R′, —OC(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″CO 2 R′, —N(R′)C(O)NR″R′″, —NR′C(NH 2 )═NR″, —S(O)R′, —SO 2 R′, —SO 2 NR′R″, —N 3 and —CH(Ph) 2 ;
optionally, two adjacent R 5 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S;
R′, R″ and R′″ are independently selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl and heteroaryl;
optionally, when R′ and R″ or R″ and R′″ are attached to the same nitrogen atom, R′ and R″ or R″ and R′″ may be combined to form a 5-, 6-, 7- or 8-membered ring containing the nitrogen atom to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and
the subscript m is 0, 1, 2, 3 or 4.
21 . A method for treating a disease or condition selected from the group consisting of asthma, allergic rhinitis, eczema, psoriasis, atopic dermatitis, fever, sepsis, systemic lupus erythematosus, diabetes, rheumatoid arthritis, multiple sclerosis, atherosclerosis, transplant rejection, inflammatory bowel disease and cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1 - 17 .
22 . A method for treating a disease or condition responsive to the modulation of CRTH2 and/or one or more other PGD 2 receptors, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
W is selected from the group consisting of aryl, heteroaryl, (C 1 -C 8 )alkyl and cyclo(C 3 -C 8 )alkyl;
L 1 is selected from the group consisting of C(O), SO 2 and (C 1 -C 4 )alkylene;
L 2 is selected from the group consisting of a single bond, C(O) and SO 2 ;
R 1 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl, aryl(C 1 -C 4 )alkoxy, aryl(C 1 -C 4 )alkenyl and heteroaryl;
R 2 and R 3 are independently hydrogen or (C 1 -C 8 )alkyl;
R 4 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl(C 1 -C 4 )alkyl, cyclo(C 3 -C 8 )alkyl(C 1 -C 4 )alkyl, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, carboxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl, carbamoyl(C 1 -C 4 )alkyl and carboxy(C 2 -C 4 )alkenyl;
each R 5 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 4 )alkoxy, thio(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, cyano, nitro, —CO 2 R′, —CONR′R″, —C(O)R′, —OC(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″CO 2 R′, —N(R′)C(O)NR″R′″, —NR′C(NH 2 )═NR″, —S(O)R′, —SO 2 R′, —SO 2 NR′R″, —N 3 and —CH(Ph) 2 ;
optionally, two adjacent R 5 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S;
R′, R″ and R′″ are independently selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl and heteroaryl;
optionally, when R′ and R″ or R″ and R′″ are attached to the same nitrogen atom, R′ and R″ or R″ and R′″ may be combined to form a 5-, 6-, 7- or 8-membered ring containing the nitrogen atom to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and
the subscript m is 0, 1, 2, 3 or 4.
23 . (Canceled)
24 . The method of claim 22 , wherein said disease or condition is selected from the group consisting of asthma, allergic rhinitis, eczema, psoriasis, atopic dermatitis, fever, sepsis, systemic lupus erythematosus, diabetes, rheumatoid arthritis, multiple sclerosis, atherosclerosis, transplant rejection, inflammatory bowel disease and cancer.
25 . The method of claim 24 , wherein said compound is administered orally, parenterally or topically.
26 . The method of claim 25 , wherein said compound is administered in combination with a second therapeutic agent.
27 . The method of claim 26 , wherein said second therapeutic agent is useful for treating asthma, allergic rhinitis, eczema, psoriasis, atopic dermatitis, fever, sepsis, systemic lupus erythematosus, diabetes, rheumatoid arthritis, multiple sclerosis, atherosclerosis, transplant rejection, inflammatory bowel disease or cancer.
28 . A method for modulating the function of CRTH2 and/or one or more other PGD 2 receptors in a cell, comprising contacting a cell with a compound of formula (I):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
W is selected from the group consisting of aryl, heteroaryl, (C 1 -C 8 )alkyl and cyclo(C 3 -C 8 )alkyl;
L 1 is selected from the group consisting of C(O), SO 2 and (C 1 -C 4 )alkylene;
L 2 is selected from the group consisting of a single bond, C(O) and SO 2 ;
R 1 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl, aryl(C 1 -C 4 )alkoxy, aryl(C 1 -C 4 )alkenyl and heteroaryl;
R 2 and R 3 are independently hydrogen or (C 1 -C 8 )alkyl;
R 4 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl(C 1 -C 4 )alkyl, cyclo(C 3 -C 8 )alkyl(C 1 -C 4 )alkyl, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, carboxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl, carbamoyl(C 1 -C 4 )alkyl and carboxy(C 2 -C 4 )alkenyl;
each R 5 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 4 )alkoxy, thio(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, cyano, nitro, —CO 2 R′, —CONR′R″, —C(O)R′, —OC(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″CO 2 R′, —N(R′)C(O)NR″R′″, —NR′C(NH 2 )═NR″, —S(O)R′, SO 2 R′, —SO 2 NR′R″, —N 3 and —CH(Ph) 2 ;
optionally, two adjacent R 5 groups may be combined to form a 5-, 6-, 7- or 8-membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S;
R′, R″ and R′″ are independently selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl and heteroaryl;
optionally, when R′ and R″ or R″ and R′″ are attached to the same nitrogen atom, R′ and R″ or R″ and R′″ may be combined to form a 5-, 6-, 7- or 8-membered ring containing the nitrogen atom to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and
the subscript m is 0, 1, 2, 3 or 4.
29 . (Canceled)
30 . A method for modulating CRTH2 and/or one or more other PGD 2 receptors, comprising contacting a CRTH2 protein and/or one or more other PGD 2 receptors proteins with a compound of formula (I):
or a pharmaceutically acceptable salt or prodrug thereof, wherein
W is selected from the group consisting of aryl, heteroaryl, (C 1 -C 8 )alkyl and cyclo(C 3 -C 8 )alkyl;
L 1 is selected from the group consisting of C(O), SO 2 and (C 1 -C 4 )alkylene;
L 2 is selected from the group consisting of a single bond, C(O) and SO 2 ;
R 1 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl, aryl(C 1 -C 4 )alkoxy, aryl(C 1 -C 4 )alkenyl and heteroaryl;
R 2 and R 3 are independently hydrogen or (C 1 -C 8 )alkyl;
R 4 is selected from the group consisting of (C 1 -C 8 )alkyl, aryl(C 1 -C 4 )alkyl, cyclo(C 3 -C 8 )alkyl(C 1 -C 4 )alkyl, hydroxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 4 )alkyl, carboxy(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxycarbonyl(C 1 -C 4 )alkyl, carbamoyl(C 1 -C 4 )alkyl and carboxy(C 2 -C 4 )alkenyl;
each R 5 is independently selected from the group consisting of halogen, (C 1 -C 8 )alkyl, (C 1 -C 4 )alkoxy, thio(C 1 -C 4 )alkoxy, amino, (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkoxy, cyano, nitro, —CO 2 R′, —CONR′R″, —C(O)R′, —OC(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″CO 2 R′, —N(R′)C(O)NR″R′″, —NR′C(NH 2 )═NR″, —S(O)R′, —SO 2 R′, —SO 2 NR′R″, —N 3 and —CH(Ph) 2 ;
optionally, two adjacent R 5 groups may be combined to form a 5-, 6-, 7- or 8membered fused ring containing the carbon atoms to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S;
R′, R″ and R′″ are independently selected from the group consisting of hydrogen, (C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 4 )alkyl and heteroaryl;
optionally, when R′ and R″ or R″ and R′″ are attached to the same nitrogen atom, R′ and R″ or R″ and R′″ may be combined to form a 5-, 6-, 7- or 8-membered ring containing the nitrogen atom to which they are attached and 0, 1 or 2 additional heteroatoms selected from N, O and S; and
the subscript m is 0, 1, 2, 3 or 4.
31 . (Canceled)
32 . The method of claim 30 , wherein said compound modulates CRTH2.
33 . The method of claim 32 , wherein said compound is a CRTH2 antagonist.